We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Lupin’s New Jersey Facility Draws FDA Warning for GMP Violations
Lupin’s New Jersey Facility Draws FDA Warning for GMP Violations
The FDA issued a warning letter to generic drugmaker Lupin for good manufacturing practice (GMP) violations observed during an inspection of its plant in Somerset, New Jersey.